XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.3

Revenues (Tables)

9 Months Ended

Sep. 30, 2024

Revenues [Abstract]

Schedule of net product revenues by product

The Company’s net revenues consisted of the following for the three and nine months ended September 30, 2024 and 2023:

			Three months ended September 30,												Nine months ended September 30,
			2024						2023						2024						2023
Products:
Kristalose			$	3,632,258					$	3,887,476					$	10,935,702					$	12,313,321
Sancuso			2,607,558						1,933,222						6,624,102						5,736,981
Vibativ			1,028,013						2,789,579						5,087,983						6,785,592
Caldolor			1,271,252						1,155,509						3,586,199						3,316,866
Acetadote			21,374						120,052						144,973						440,071
Omeclamox-Pak			(18)						23,288						(2,574)						28,832
Vaprisol			(135,765)						—						(128,684)						39,866
RediTrex			36,950						(122,556)						71,350						(254,108)
Other revenue			624,204						299,356						1,113,325						1,792,020
Total net revenues			$	9,085,826					$	10,085,926					$	27,432,376					$	30,199,441

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenuesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration